Affiliation: Bristol-Myers Squibb
- Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virusG Yamanaka
Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492 7660, USA
Antimicrob Agents Chemother 43:190-3. 1999..Compared with five other nucleoside analogs of medical interest (lamivudine, penciclovir, ganciclovir, acyclovir, and lobucavir), BMS-200475 was most efficiently phosphorylated to the triphosphate in HepG2 cells...
- Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymeraseD J Tenney
Department of Virology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA
Antimicrob Agents Chemother 41:2680-5. 1997..Furthermore, LBV may be effective in the treatment of GCV-resistant HCMV...
- Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitroS Levine
Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
Antimicrob Agents Chemother 46:2525-32. 2002..These findings are predictive of potent antiviral activity of ETV against both wild-type and 3TC-resistant HBV...